预防B群脑膜炎球菌病的国家疫苗接种政策比较
该综述全面审查了58个已批准蛋白基B群脑膜炎球菌疫苗(Bexsero®和Trumenba®)使用的国家的政策与实践,发现24个国家有国家MenB疫苗接种政策,其中15国将MenB疫苗纳入至少一个年龄风险组的免疫规划,21国针对基础疾病风险组发布推荐,13国针对暴露风险增高组发布推荐;推荐接种程序和剂次差异很大,大多数国家未获得年龄风险组的接种覆盖率数据。结论强调各国MenB疫苗接种推荐存在显著异质性,提高推荐报告透明度和实施数据有助于优化预防策略。
要点
- 58个批准MenB疫苗的国家中24个有国家接种政策。
- 15国将MenB疫苗纳入年龄风险组免疫规划,多针对婴儿。
- 推荐接种程序和剂次在各国间差异很大。
核心结论
- 各国MenB疫苗接种推荐存在显著异质性。
- 提高推荐报告透明度和实施数据有助于优化MenB预防策略。
研究设计与样本
- 对58个已批准蛋白基MenB疫苗(Bexsero®和Trumenba®)使用的国家的政策与实践进行综合审查。
- 检索PubMed、卫生部及其他相关机构网站以识别政策文件与计划,收集实施时间线、目标人群、使用疫苗、推荐程序及覆盖率数据,并联系专家补充细节。
主要发现
- 58个国家中24个有国家MenB疫苗接种政策证据。
- 24国中15国将MenB疫苗接种纳入至少一个年龄风险组(多为婴儿)的免疫规划。
- 24国中21国针对基础疾病风险组(如无脾)发布推荐,13国针对暴露风险增高组(如实验室人员)发布推荐。
- 推荐接种程序和剂次(若有)差异很大,大多数国家未获得年龄风险组的接种覆盖率数据。
局限性
- 大多数国家未获得年龄风险组的接种覆盖率数据。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To understand the global landscape of prevention and control efforts targeting serogroup B meningococcal (MenB) disease and to identify the key challenges and gaps yet to be addressed. METHODS: We conducted a comprehensive review of policies and practices for the use of protein-based MenB vaccines (Bexsero® [GlaxoSmithKline] and Trumenba® [Pfizer]) in all countries (n = 58) where either or both vaccine is authorized for use. We searched the literature (PubMed) and websites of health ministries and other relevant agencies to identify policy documents and plans and collect information about implementation timelines, target groups, vaccines being used, recommended schedules, and coverage data. Experts in the field were contacted for additional details andclarifications, as needed. RESULTS: We found evidence of a national MenB vaccination policy in 24 out of 58 countries where one or both protein-based MenB vaccines are authorized. Of these, 15 countries have included MenB vaccination in their immunization plans for at least one age-based risk group (mostly infants), 21 have issued recommendations for various risk groups based on underlying medical conditions (e.g. asplenia), and 13 have done so for select groups at increased risk of exposure (e.g. laboratory staff). Recommended vaccination schedules and number of doses, where available, varied widely. Vaccination coverage data for age-based risk groups were not obtained for most countries. CONCLUSIONS: Our findings highlighted the significant heterogeneity in recommendations for MenB vaccination across countries. Greater transparency in reporting MenB vaccination recommendations and more robust data on implementation and the impact of vaccination would better facilitate optimizing MenB prevention strategies.
引用
- Sulis G, Horn M, Borrow R, et al. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine. 2022. PMID: 35581099. doi:10.1016/j.vaccine.2022.04.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。